For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Rush University Medical Center
Conditions and Treatments
Search by Topic or Doctor's Name
Doctors at Rush Focus on You
At the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.
— Octavio Vega, MD, internist
I enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.
— Patricia Graham, MD, internist
Hear more from doctors at Rush.
Directions and Parking
Health & Wellness
Health News and Advice to Fit Your Life
The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.
5 Things You Can Do to Prevent CancerHow you can devise a cancer prevention action plan.
Combating Social Media DysmorphiaHow to love yourself — and your selfies — without filters or fillers.
About RushThe Rush SystemPatient StoriesNational Recognition and AccreditationsRush News
Quality and Safety at RushPatient Satisfaction and FeedbackRush in the CommunityDiversity and Inclusion
Disability Rights and AccommodationsCommitment to LGBTQ Health CareVolunteeringBondholder Information
A study of itacitinib or placebo in combination with corticosteroids for treatment of acute graft-versus-host disease.
Safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients with hemophilia A.
Knowledge and improvement of health literacy and numeracy in adolescent patients with hemophilia A and B.
A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant Factor VIIa (MOD-5014) in adult men with hemophilia A or B, with or without inhibitors.
Prospective, open-label multicenter phase 3b to assess the efficacy and safety of personalized prophylaxis with Human-cl rh-FVIII in previously treated adult with severe hemophilia A.
Molecular and clinical biology of von Willebrand disease.
The American Thrombosis and Hemostasis Network (ATHN) national registry of all persons with bleeding and clotting disorders.
Public health surveillance for the prevention of complications of bleeding and clotting disorders.
Expression of biomarkers in hemophilic arthropathy: Repository of surgical tissue samples and biomarkers in patients with hemophilia.
Hepatitis C virus (HCV) outcomes after treatment with direct acting agents (DAA) in patients with bleeding disorders.